Japanese Yen consolidates against US Dollar amid uncertainty over future of Middle East
The Japanese Yen (JPY) trades flat against the US Dollar (USD) at around 162.50 during the Asian trading session on Tuesday, closer to its multi-decade high of 162.84. The USD/JPY pair will likely remain sideways as investors seek fresh cues regarding whether the United States (US) and Iran will announce a ceasefire or will continue exchanging attacks.
In the Asian trade, the US Dollar Index (DXY), which gauges the Greenback’s value against six major currencies, trades flat around 101.00.
According to a report from Axios, US President Donald Trump will either accept the 10-day ceasefire with Iran and resume negotiations towards an interim deal or call for a joint full-scale military campaign with Israel against Iran.
On Monday, a senior Iranian official confirmed receiving a proposal for a 10-day ceasefire from mediators to resume talks on an interim deal.
On the domestic front, investors await Japan’s National Consumer Price Index (CPI) data for June, which will be released on Friday. Investors will pay close attention to the inflation data to get cues regarding the Bank of Japan’s (BoJ) monetary policy outlook. The National CPI ex. Fresh Food is expected to arrive at 1.6% Year-on-Year (YoY), higher than 1.4% in May.
Meanwhile, the next key trigger for the US Dollar will be the preliminary S&P Global PMI data for July, which will be released on Thursday.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New Non-Opioid Pain Relief Company Latigo (LTGO.US) Plans IPO to Raise Up to $288 Million, Nav1.8 Inhibitor Targets Vertex Pharmaceuticals (VRTX.US) Billion-Dollar Market
Pain therapy biotechnology company Latigo Biotherapeutics has finalized the terms for a $272 million IPO.
Euro holds ground as Eurozone growth data offsets oil-driven CAD gains
Earnings Preview | Pfizer (PFE.US) and Merck (MRK.US) Announce Results on the Same Day: As Patent Cliff Meets New Growth Engines, the Pharmaceutical Industry Faces a Valuation Test
Pfizer and Merck released their Q2 earnings report on the same day: one faces the major test of the “post-COVID era,” while the other is making a final push before the impending patent cliff for Keytruda.
Amazon (AMZN.US) surges 20% in two days: AWS's accelerated growth validates AI demand, concerns rise over capital expenditures and depreciation pressure
Some cautious market participants believe that what is truly validated for Amazon is the demand for AI, rather than the relationship between construction costs and actual economic returns. This suggests that Amazon’s stock price may once again come under pressure in the future due to the drag from capital expenditures.
Crypto prices
More
